Reviewing Ramsay Health Care (OTCMKTS:RMSYF) & Interpace Biosciences (OTCMKTS:IDXG)

Interpace Biosciences (OTCMKTS:IDXG) and Ramsay Health Care (OTCMKTS:RMSYF) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, valuation and dividends.

Earnings and Valuation

This table compares Interpace Biosciences and Ramsay Health Care”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Interpace Biosciences	$38.73 million	0.17	$24.58 million	$0.08	18.12
Ramsay Health Care	N/A	N/A	N/A	$1.43	20.69

Interpace Biosciences has higher revenue and earnings than Ramsay Health Care. Interpace Biosciences is trading at a lower price-to-earnings ratio than Ramsay Health Care, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Interpace Biosciences and Ramsay Health Care’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Interpace Biosciences	67.64%	145.40%	87.36%
Ramsay Health Care	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of recent ratings for Interpace Biosciences and Ramsay Health Care, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Interpace Biosciences	0	0	0	0	0.00
Ramsay Health Care	0	0	1	0	3.00

Ramsay Health Care has a consensus price target of $54.10, suggesting a potential upside of 82.89%. Given Ramsay Health Care’s stronger consensus rating and higher possible upside, analysts clearly believe Ramsay Health Care is more favorable than Interpace Biosciences.

Insider & Institutional Ownership

5.7% of Interpace Biosciences shares are held by institutional investors. Comparatively, 13.2% of Ramsay Health Care shares are held by institutional investors. 0.9% of Interpace Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Ramsay Health Care beats Interpace Biosciences on 6 of the 11 factors compared between the two stocks.

About Interpace Biosciences

Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.

About Ramsay Health Care

Ramsay Health Care Limited owns and operates hospitals. The company offers health care services to public and private patients. It operates facilities in approximately 530 locations in the Asia Pacific, the United Kingdom, France, and Nordics. Ramsay Health Care Limited was founded in 1964 and is based in Sydney, Australia.